Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1964 1
1967 2
1968 3
1971 1
1977 1
1978 2
1979 1
1981 2
1982 1
1983 1
1984 1
1994 2
1997 1
1999 1
2000 1
2008 3
2009 1
2010 1
2011 3
2013 1
2014 1
2015 3
2018 1
2019 1
2020 3
2021 4
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial.
Röth A, Berentsen S, Barcellini W, D'Sa S, Jilma B, Michel M, Weitz IC, Yamaguchi M, Nishimura JI, Vos JMI, Storek M, Wong N, Patel P, Jiang X, Vagge DS, Wardęcki M, Shafer F, Lee M, Broome CM. Röth A, et al. Blood. 2022 Sep 1;140(9):980-991. doi: 10.1182/blood.2021014955. Blood. 2022. PMID: 35687757 Free PMC article. Clinical Trial.
Sutimlimab, a first-in-class humanized immunoglobulin G4 (IgG4) monoclonal antibody that selectively inhibits the classical complement pathway at C1s, rapidly halted hemolysis in the single-arm CARDINAL study in recently transfused patients with cold agglutinin disease (CA …
Sutimlimab, a first-in-class humanized immunoglobulin G4 (IgG4) monoclonal antibody that selectively inhibits the classical complement pathw …
Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia.
Chalandon Y, Thomas X, Hayette S, Cayuela JM, Abbal C, Huguet F, Raffoux E, Leguay T, Rousselot P, Lepretre S, Escoffre-Barbe M, Maury S, Berthon C, Tavernier E, Lambert JF, Lafage-Pochitaloff M, Lhéritier V, Chevret S, Ifrah N, Dombret H; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). Chalandon Y, et al. Blood. 2015 Jun 11;125(24):3711-9. doi: 10.1182/blood-2015-02-627935. Epub 2015 Apr 15. Blood. 2015. PMID: 25878120 Free article. Clinical Trial.
Personality of patients with fecal incontinence.
Bouchoucha M, Devroede G, Deutsch D, Raynaud JJ, Sabate JM, Benamouzig R. Bouchoucha M, et al. Int J Colorectal Dis. 2021 Feb;36(2):331-337. doi: 10.1007/s00384-020-03758-w. Epub 2020 Oct 1. Int J Colorectal Dis. 2021. PMID: 33000298
Course of mixed connective tissue disease in children.
Michels H. Michels H. Ann Med. 1997 Oct;29(5):359-64. doi: 10.3109/07853899708999362. Ann Med. 1997. PMID: 9453280 Review.
Mixed connective tissue disease (MCTD) was first reported 25 years ago. This report provides an assessment of the course of juvenile (J) MCTD in 224 patients available in the literature until 1996, including our own 33 patients. ...Cardiovascular problems observed include …
Mixed connective tissue disease (MCTD) was first reported 25 years ago. This report provides an assessment of the course of juvenile …
Clinical and Serological Characteristics of a Monocentric Cohort of Patients Affected by Interstitial Pneumonia with Autoimmune Features (IPAF).
Canofari C, Vendola A, Iuliano A, Di Michele L, Sebastiani A, Gubbiotti A, Sebastiani GD. Canofari C, et al. Mediterr J Rheumatol. 2023 Jun 30;34(2):180-187. doi: 10.31138/mjr.34.2.180. eCollection 2023 Jun. Mediterr J Rheumatol. 2023. PMID: 37654644 Free PMC article.
RESULTS: 36 consecutive IPAF patients were enrolled from January 2021 to January 2022. Raynaud's phenomenon was the most frequent symptom identified. We also described other signs and symptoms not included in IPAF criteria. 36,1% of patients demonstrated a Usual Int …
RESULTS: 36 consecutive IPAF patients were enrolled from January 2021 to January 2022. Raynaud's phenomenon was the most frequ …
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.
Rodon J, Soria JC, Berger R, Miller WH, Rubin E, Kugel A, Tsimberidou A, Saintigny P, Ackerstein A, Braña I, Loriot Y, Afshar M, Miller V, Wunder F, Bresson C, Martini JF, Raynaud J, Mendelsohn J, Batist G, Onn A, Tabernero J, Schilsky RL, Lazar V, Lee JJ, Kurzrock R. Rodon J, et al. Nat Med. 2019 May;25(5):751-758. doi: 10.1038/s41591-019-0424-4. Epub 2019 Apr 22. Nat Med. 2019. PMID: 31011205 Free PMC article. Clinical Trial.
The most common diagnoses were colon, head and neck, and lung cancers. Among the 107 patients, the rate of stable disease 6 months and partial or complete response was 26.2% (arm A: 23.2%; arm B: 31.6% (P = 0.37)). ...
The most common diagnoses were colon, head and neck, and lung cancers. Among the 107 patients, the rate of stable disease 6 months an …
Accuracy of citrulline, I-FABP and D-lactate in the diagnosis of acute mesenteric ischemia.
Nuzzo A, Guedj K, Curac S, Hercend C, Bendavid C, Gault N, Tran-Dinh A, Ronot M, Nicoletti A, Bouhnik Y, Castier Y, Corcos O, Peoc'h K; SURVI (Structure d’URgences Vasculaires Intestinales) Research Group (French Intestinal Stroke Center). Nuzzo A, et al. Sci Rep. 2021 Sep 23;11(1):18929. doi: 10.1038/s41598-021-98012-w. Sci Rep. 2021. PMID: 34556697 Free PMC article.
44 results